122 related articles for article (PubMed ID: 20582983)
41. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature.
Saito S; Yanagisawa R; Yoshikawa K; Higuchi Y; Koya T; Yoshizawa K; Tanaka M; Sakashita K; Kobayashi T; Kurata T; Hirabayashi K; Nakazawa Y; Shiohara M; Yonemitsu Y; Okamoto M; Sugiyama H; Koike K; Shimodaira S
Cytotherapy; 2015 Mar; 17(3):330-5. PubMed ID: 25484308
[TBL] [Abstract][Full Text] [Related]
42. WT1-targeted immunotherapy of leukaemia.
Xue S; Gao L; Gillmore R; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Stauss HJ; Morris E
Blood Cells Mol Dis; 2004; 33(3):288-90. PubMed ID: 15528146
[TBL] [Abstract][Full Text] [Related]
43. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
45. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
46. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
47. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
48. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
49. [Cancer antigen WT1-targeting treatment for the malignancies].
Oka Y; Kawase I
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
[TBL] [Abstract][Full Text] [Related]
50. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.
Cebinelli GC; DE Sousa Pereira N; Sena MM; DE Oliveira CE; Fujita TC; DA Rocha SP; DE Abreu Oliveira FJ; Marinello PC; Watanabe MA
Anticancer Res; 2016 Aug; 36(8):3795-802. PubMed ID: 27466479
[TBL] [Abstract][Full Text] [Related]
52. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
Kawakami M; Oka Y; Tsuboi A; Harada Y; Elisseeva OA; Furukawa Y; Tsukaguchi M; Shirakata T; Nishida S; Nakajima H; Morita S; Sakamoto J; Kawase I; Oji Y; Sugiyama H
Int J Hematol; 2007 Jun; 85(5):426-9. PubMed ID: 17562620
[TBL] [Abstract][Full Text] [Related]
53. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
Kato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
[TBL] [Abstract][Full Text] [Related]
54. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H
Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768
[No Abstract] [Full Text] [Related]
55. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
Nishida S; Sugiyama H
Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
[TBL] [Abstract][Full Text] [Related]
57. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.
Borbulevych OY; Do P; Baker BM
Mol Immunol; 2010 Sep; 47(15):2519-24. PubMed ID: 20619457
[TBL] [Abstract][Full Text] [Related]
58. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.
Oka Y; Sugiyama H
Immunotherapy; 2010 Sep; 2(5):591-4. PubMed ID: 20874639
[No Abstract] [Full Text] [Related]
59. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
Miyatake T; Ueda Y; Morimoto A; Enomoto T; Nishida S; Shirakata T; Oka Y; Tsuboi A; Oji Y; Hosen N; Nakatsuka S; Morita S; Sakamoto J; Sugiyama H; Kimura T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):457-63. PubMed ID: 23160854
[TBL] [Abstract][Full Text] [Related]
60. [WT1 peptide cancer vaccine].
Sugiyama H
Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
